Revision of the criteria for Alzheimer's disease: A symposium.

Steven T. DeKosky, Maria C. Carrillo, Creighton Phelps, David S Knopman, Ronald Carl Petersen, Richard Frank, Dale Schenk, Donna Masterman, Eric R. Siemers, Jesse M. Cedarbaum, Michael Gold, David S. Miller, Bruce H. Morimoto, Ara S. Khachaturian, Richard C. Mohs

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The current criteria for classification of Alzheimer's disease (AD) have deficiencies that limit drug development, research, and practice. The current standard for the clinical diagnosis of AD, the National Institute of Neurological and Communicative Disorders and Stroke (now known as the National Institute of Neurological Disorders and Stroke), and the Alzheimer's Disease and Related Disorders Association (now known as the Alzheimer's Association) criteria, are nearly 25 years old and have not been revised to incorporate advances in the epidemiology and genetics of AD, studies of clinicopathologic correlations and recent studies of potential diagnostic biomarkers. In a very real sense our ability to diagnose AD with a very high level of certainty has outpaced our current diagnostic criteria. The Alzheimer's Association Research Roundtable convened a meeting in April 2009 to discuss new data and technologies that could, with further development, enable improvements in the clinical diagnosis of AD, especially in its earliest and mildest stages. This meeting reviewed the current standards for detecting and defining the clinical presentation of AD and discussed areas that could contribute to earlier and more accurate definitive clinical diagnosis. These included clinical, neuropsychological, and other performance-based assessments, genetic contributions, and biochemical and neuroimaging biomarkers that could reflect AD pathology and lead to better ascertainment of AD, mild cognitive impairment, and presymptomatic AD.

Original languageEnglish (US)
JournalAlzheimer's & dementia : the journal of the Alzheimer's Association
Volume7
Issue number1
StatePublished - Jan 2011

Fingerprint

Alzheimer Disease
National Institute of Neurological Disorders and Stroke
Biomarkers
Communication Disorders
Asymptomatic Diseases
Inborn Genetic Diseases
Aptitude
Research
Neuroimaging
Molecular Biology
Epidemiology
Pathology
Technology
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Revision of the criteria for Alzheimer's disease : A symposium. / DeKosky, Steven T.; Carrillo, Maria C.; Phelps, Creighton; Knopman, David S; Petersen, Ronald Carl; Frank, Richard; Schenk, Dale; Masterman, Donna; Siemers, Eric R.; Cedarbaum, Jesse M.; Gold, Michael; Miller, David S.; Morimoto, Bruce H.; Khachaturian, Ara S.; Mohs, Richard C.

In: Alzheimer's & dementia : the journal of the Alzheimer's Association, Vol. 7, No. 1, 01.2011.

Research output: Contribution to journalArticle

DeKosky, ST, Carrillo, MC, Phelps, C, Knopman, DS, Petersen, RC, Frank, R, Schenk, D, Masterman, D, Siemers, ER, Cedarbaum, JM, Gold, M, Miller, DS, Morimoto, BH, Khachaturian, AS & Mohs, RC 2011, 'Revision of the criteria for Alzheimer's disease: A symposium.', Alzheimer's & dementia : the journal of the Alzheimer's Association, vol. 7, no. 1.
DeKosky, Steven T. ; Carrillo, Maria C. ; Phelps, Creighton ; Knopman, David S ; Petersen, Ronald Carl ; Frank, Richard ; Schenk, Dale ; Masterman, Donna ; Siemers, Eric R. ; Cedarbaum, Jesse M. ; Gold, Michael ; Miller, David S. ; Morimoto, Bruce H. ; Khachaturian, Ara S. ; Mohs, Richard C. / Revision of the criteria for Alzheimer's disease : A symposium. In: Alzheimer's & dementia : the journal of the Alzheimer's Association. 2011 ; Vol. 7, No. 1.
@article{2e550e40e81f44009dd6a5176886aea5,
title = "Revision of the criteria for Alzheimer's disease: A symposium.",
abstract = "The current criteria for classification of Alzheimer's disease (AD) have deficiencies that limit drug development, research, and practice. The current standard for the clinical diagnosis of AD, the National Institute of Neurological and Communicative Disorders and Stroke (now known as the National Institute of Neurological Disorders and Stroke), and the Alzheimer's Disease and Related Disorders Association (now known as the Alzheimer's Association) criteria, are nearly 25 years old and have not been revised to incorporate advances in the epidemiology and genetics of AD, studies of clinicopathologic correlations and recent studies of potential diagnostic biomarkers. In a very real sense our ability to diagnose AD with a very high level of certainty has outpaced our current diagnostic criteria. The Alzheimer's Association Research Roundtable convened a meeting in April 2009 to discuss new data and technologies that could, with further development, enable improvements in the clinical diagnosis of AD, especially in its earliest and mildest stages. This meeting reviewed the current standards for detecting and defining the clinical presentation of AD and discussed areas that could contribute to earlier and more accurate definitive clinical diagnosis. These included clinical, neuropsychological, and other performance-based assessments, genetic contributions, and biochemical and neuroimaging biomarkers that could reflect AD pathology and lead to better ascertainment of AD, mild cognitive impairment, and presymptomatic AD.",
author = "DeKosky, {Steven T.} and Carrillo, {Maria C.} and Creighton Phelps and Knopman, {David S} and Petersen, {Ronald Carl} and Richard Frank and Dale Schenk and Donna Masterman and Siemers, {Eric R.} and Cedarbaum, {Jesse M.} and Michael Gold and Miller, {David S.} and Morimoto, {Bruce H.} and Khachaturian, {Ara S.} and Mohs, {Richard C.}",
year = "2011",
month = "1",
language = "English (US)",
volume = "7",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Revision of the criteria for Alzheimer's disease

T2 - A symposium.

AU - DeKosky, Steven T.

AU - Carrillo, Maria C.

AU - Phelps, Creighton

AU - Knopman, David S

AU - Petersen, Ronald Carl

AU - Frank, Richard

AU - Schenk, Dale

AU - Masterman, Donna

AU - Siemers, Eric R.

AU - Cedarbaum, Jesse M.

AU - Gold, Michael

AU - Miller, David S.

AU - Morimoto, Bruce H.

AU - Khachaturian, Ara S.

AU - Mohs, Richard C.

PY - 2011/1

Y1 - 2011/1

N2 - The current criteria for classification of Alzheimer's disease (AD) have deficiencies that limit drug development, research, and practice. The current standard for the clinical diagnosis of AD, the National Institute of Neurological and Communicative Disorders and Stroke (now known as the National Institute of Neurological Disorders and Stroke), and the Alzheimer's Disease and Related Disorders Association (now known as the Alzheimer's Association) criteria, are nearly 25 years old and have not been revised to incorporate advances in the epidemiology and genetics of AD, studies of clinicopathologic correlations and recent studies of potential diagnostic biomarkers. In a very real sense our ability to diagnose AD with a very high level of certainty has outpaced our current diagnostic criteria. The Alzheimer's Association Research Roundtable convened a meeting in April 2009 to discuss new data and technologies that could, with further development, enable improvements in the clinical diagnosis of AD, especially in its earliest and mildest stages. This meeting reviewed the current standards for detecting and defining the clinical presentation of AD and discussed areas that could contribute to earlier and more accurate definitive clinical diagnosis. These included clinical, neuropsychological, and other performance-based assessments, genetic contributions, and biochemical and neuroimaging biomarkers that could reflect AD pathology and lead to better ascertainment of AD, mild cognitive impairment, and presymptomatic AD.

AB - The current criteria for classification of Alzheimer's disease (AD) have deficiencies that limit drug development, research, and practice. The current standard for the clinical diagnosis of AD, the National Institute of Neurological and Communicative Disorders and Stroke (now known as the National Institute of Neurological Disorders and Stroke), and the Alzheimer's Disease and Related Disorders Association (now known as the Alzheimer's Association) criteria, are nearly 25 years old and have not been revised to incorporate advances in the epidemiology and genetics of AD, studies of clinicopathologic correlations and recent studies of potential diagnostic biomarkers. In a very real sense our ability to diagnose AD with a very high level of certainty has outpaced our current diagnostic criteria. The Alzheimer's Association Research Roundtable convened a meeting in April 2009 to discuss new data and technologies that could, with further development, enable improvements in the clinical diagnosis of AD, especially in its earliest and mildest stages. This meeting reviewed the current standards for detecting and defining the clinical presentation of AD and discussed areas that could contribute to earlier and more accurate definitive clinical diagnosis. These included clinical, neuropsychological, and other performance-based assessments, genetic contributions, and biochemical and neuroimaging biomarkers that could reflect AD pathology and lead to better ascertainment of AD, mild cognitive impairment, and presymptomatic AD.

UR - http://www.scopus.com/inward/record.url?scp=79955670031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955670031&partnerID=8YFLogxK

M3 - Article

C2 - 21322828

AN - SCOPUS:79955670031

VL - 7

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 1

ER -